Patient-reported health-related quality of life from a randomized, placebo-controlled phase 2 trial of zuranolone in adults with major depressive disorder.
J Affect Disord
; 308: 19-26, 2022 07 01.
Article
de En
| MEDLINE
| ID: mdl-35378149
Mots clés
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Trouble dépressif majeur
Type d'étude:
Clinical_trials
/
Prognostic_studies
Aspects:
Patient_preference
Limites:
Adult
/
Humans
Langue:
En
Journal:
J Affect Disord
Année:
2022
Type de document:
Article